The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Multidrug-resistant (MDR) gram-negative bacilli pose a significant global health threat.
• Antibiotic development for gram-negative infections has not kept pace with gram-positive pathogens.
• Existing antibiotic pipelines are insufficient to combat the rising threat of MDR infections.

Purpose of the Study:

• To highlight the critical need for novel antibiotic development against MDR gram-negative pathogens.
• To emphasize the importance of preserving the efficacy of current antibiotics.
• To advocate for a robust pipeline of safe and effective antibacterial agents.

Main Methods:

• Review of current antibiotic development landscape for gram-negative infections.
• Analysis of challenges in developing new antibacterials.
• Assessment of strategies for antimicrobial stewardship.

Main Results:

• Significant lag in antibiotic development for MDR gram-negative bacilli compared to gram-positive pathogens.
• Limited number of promising drugs in early clinical development.
• Urgent need for strategies to maintain current antibiotic effectiveness.

Conclusions:

• The development of new antibiotics against multidrug-resistant gram-negative bacteria is critically insufficient.
• Preserving the utility of existing antibiotics and ensuring a future pipeline are paramount.
• Continued research and investment are essential to combat the growing threat of antimicrobial resistance.